HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 34, 30838-30843, August 23, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/34/30838    most recent M204078200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, Y. Articles by Lu, H. Search for Related Content PubMed PubMed Citation Articles by Jin, Y. Articles by Lu, H. Social Bookmarking                      What's this?

MDM2 Inhibits PCAF (p300/CREB-binding Protein-associated Factor)-mediated p53 Acetylation^*

Yetao Jin, Shelya X. Zeng, Mu-Shui Dai, Xiang-Jiao Yang, and Hua Lu^§

From the Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, Oregon 97201 and the  Molecular Oncology Group, Department of Medicine, McGill University Health Center, Montreal, Quebec H3A 1A1, Canada

Received for publication, April 25, 2002, and in revised form, June 13, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Our previous study shows that MDM2, a negative feedback regulator of the tumor suppressor p53, inhibits p300-mediated p53 acetylation. Because PCAF (p300/CREB-binding protein-associated factor) also acetylates and activates p53 after DNA damage, in this study we have examined the effect of MDM2 on PCAF-mediated p53 acetylation. We have found that MDM2 inhibited p53 acetylation by PCAF in vitro. In addition, when overexpressed, MDM2 inhibited PCAF-mediated p53 acetylation in cells. MDM2 interacted with PCAF both in vitro and in cells, as assessed using GST fusion protein interaction and immunoprecipitation assays, respectively. Consistent with the above results, MDM2 significantly repressed the activation of p53 transcriptional activity by PCAF without apparently affecting the level of p53. In addition, MDM2 co-resided with p53 at the p53-responsive mdm2 and p21^waf1/cip1 promoters, inhibiting expression of the endogenous p21^waf1/cip1. These results demonstrate that MDM2 can inhibit PCAF-mediated p53 acetylation and activation.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The tumor suppressor p53 protein is a transcriptional activator that induces expression of many target genes whose protein products mediate p53-dependent cell growth arrest and apoptosis, thus suppressing cell transformation and tumorigenesis (1, 2). This protein is tightly regulated under physiological and pathological conditions. Post-translational modifications of p53 play crucial but different roles in regulating p53 stability and activity (3). For example, phosphorylation of p53, stimulated by UV and  irradiation, stabilizes p53 and subsequently activates its activity (4-11). In addition, p53 is acetylated at several C-terminal lysines in response to genotoxic agents (12-14). One group of acetylases, p300 and CBP,¹ has been shown to acetylate p53 in vitro and in cells (12, 14-16). Thus, by acetylating p53, p300/CBP may stabilize and activate p53 (17-20). Although less studied, the p300/CBP-associated factor (PCAF) has also been shown to specifically acetylate the lysine 320 of p53, leading to the enhancement of the sequence-specific DNA binding activity of p53 in vitro (13). The acetylation at lysine 320 is responsive to DNA damage as well (12, 13). Hence, these types of modifications generally result in up-regulation of p53 function. Consistent with this, deacetylation of p53 by HDAC1 and Sir2 deacetylases has been recently shown to inactivate p53 function (21-24). Additionally, adenovirus E1A and E1B 55-kDa oncoproteins inhibit p53 acetylation catalyzed by PCAF (25, 26).

However, p53 is also negatively regulated by post-translational ubiquitination. This modification is mediated by the p53 suppressor, MDM2, which possesses a Ring finger E3-like ubiquitin ligase activity (27-29). It is believed that under physiological or normal conditions, the turnover rate of p53 is controlled by MDM2 through the ubiquitin-mediated proteasome system (30-32). Upon cellular insults, p53 is phosphorylated and/or acetylated (3). These modifications prevent p53 from attack by MDM2. Thus, p53 becomes stabilized and activated, transcriptionally activating the expression of its target genes. Because mdm2 is a p53 target (33, 34), more MDM2 proteins are produced after DNA damage to repress p53 function. Hence, under pathological or abnormal conditions, MDM2 must antagonize multiple enzymes, including kinases and acetylases, in order to monitor p53 function. How these proteins interplay to finely tune p53 activity becomes an important question.

In an attempt to address this issue, we (16) and others (14) have recently shown that MDM2 inhibits p53 acetylation by p300 both in vitro and in vivo. Functionally, MDM2 blocked the ability of p300 to stimulate the sequence-specific DNA binding and transcriptional activities of p53 (16). Because interaction between p53 and MDM2 or MDM2 and p300 is required for inhibiting p300-mediated p53 acetylation by MDM2, MDM2 inhibits p53 acetylation by forming a ternary complex with p53 and p300 (16). This finding prompted us to determine whether MDM2 is able to inhibit PCAF-mediated p53 acetylation and activation. In the study described here, we found that MDM2 inhibited p53 acetylation by PCAF in vitro. Furthermore, when overexpressed in cells, MDM2 inhibited PCAF-mediated p53 acetylation in vivo. MDM2 interacted with PCAF both in vitro and in cells, as assessed using GST fusion protein interaction and immunoprecipitation assays. In addition, MDM2 significantly repressed the activation of p53 transcriptional activity by PCAF. These results demonstrate that MDM2 can also inhibit PCAF-mediated p53 acetylation and activation. These studies support the idea that after DNA damage, MDM2, once induced by p53, needs to prevent p53 acetylation in order to efficiently ubiquitinate and degrade this protein.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Cell Culture-- Human lung small cell carcinoma H1299 cells and human embryonic kidney epithelial 293 cells were cultured as previously described (35, 36).

Buffers-- Lysis buffer consisted of 50 mM Tris/HCl (pH 8.0), 0.5% Nonidet P-40, 1 mM EDTA, 150 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride. SNNTE buffer contained 50 mM Tris/HCl (pH 7.4), 5 mM EDTA, 1% Nonidet P-40, 500 mM NaCl, and 5% sucrose. RIPA was comprised of 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1% (w/v) sodium deoxycholate. Buffer C 100 (BC100) included 20 mM Tris/HCl (pH 7.9), 0.1 mM EDTA, 10% glycerol, 100 mM KCl, 4 mM MgCl₂, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and 0.25 µg/ml pepstatin A.

Antibodies and Reagents-- The anti-acetylated lysine antibody and anti-acetylated lysine 320 antibody were purchased from Upstate Biotechnology, Inc. The monoclonal anti-FLAG antibody was purchased from Sigma. The monoclonal anti-p53 antibody Pab421 and polyclonal or monoclonal anti-MDM2 antibodies, 4B11 and 2A10, were described previously (37). Polyclonal anti-PCAF antibodies (H-369 and FL-393) and monoclonal anti-JNK1 (F-3) antibodies were purchased from Santa Cruz Biotechnology, Inc. Baculovirus harboring human PCAF, p300, or MDM2 was as previously described (37-39). pCDNA3-MDM2, pCMV-p53, pCDNA3-N-MDM2, and pCDNA3-150-230 (MDM2) were as described (40). pCX-FLAG-PCAF was described previously (39).

Construction of pRSV-PCAF, pRSV-PCAF/1-- 529, and pRSV-PCAF/66-466 PlasmidsTo express PCAF under the control of the RSV and T7 promoters, NcoI and KpnI sites were first introduced at the translation initiation codon and after the stop codon of the PCAF coding sequence, respectively. The full-length coding sequence was then cloned between the NcoI and KpnI sites of the expression vector pExpress-O (41). pRSV-1-529 was constructed similarly by creating NcoI and KpnI sites at the translation initiation codon and after the codon for residue 529, respectively. A stop codon was also inserted between codon 529 and the KpnI site. The resulting 1.6-kb NcoI/KpnI fragment was subsequently cloned between the NcoI and KpnI sites of pExpress-O (41). pRSV-66-466 was constructed by digesting pRSV-PCAF with PstI, followed by subsequent religation. These vectors were used for in vitro translation of PCAF and PCAF deletion mutants with the TNT translation kit (Invitrogen).

Purification of Recombinant p300, PCAF, MDM2, and p53-- PCAF and p300 were purified from baculovirus-infected SF9 insect cells using immunoaffinity columns as described (37, 39). His-p53 was purified from bacteria using a nickel-nitrilotriacetic acid column as described (37, 38). MDM2 and p53 were purified using an immunoaffinity column as described (37).

Establishment of HA-MDM2 Expression Cell Lines-- Human embryonic kidney epithelial 293 cells were transfected with pCDNA3-HA-MDM2 or pCDNA3 vector. Transfected cells expressing HA-MDM2 were selected in the presence of neomycin (0.5 mg/ml) and screened by immunoprecipitation with anti-HA antibodies followed by Western blot with the monoclonal anti-MDM2 antibody 2A10.

p53 Acetylation Reaction-- p53 acetylation assays were carried out according to the published method (16). 20 µl of reaction mixture contained 50 mM Tris/Hcl (pH 8.0), 10% glycerol (v/v), 0.1 mM EDTA, 1 mM dithiothreitol, 10 mM Na butyrate, 5 µM acetyl-CoA (Sigma), 50 ng of p53, 200 ng of p300, 200 ng of PCAF, and MDM2 (see figure legends for the amount of MDM2 used in each reaction). MDM2 was preincubated with p300 or PCAF in ice for 30 min prior to being added into the reaction mixture containing acetyl-CoA. The mixture was then incubated at 30 °C for 60 min and analyzed on SDS-PAGE afterward. Acetylated p53 was detected by Western blot using the polyclonal anti-acetylated lysine antibody. Monoclonal anti-p53 antibody 421, polyclonal anti-MDM2 antibody, and polyclonal anti-p300 or polyclonal anti-PCAF antibody from Upstate Biotechnology were used to detect corresponding proteins.

Western Blot Analysis-- Transfected cells were harvested for preparation of nuclear extracts. Nuclear extracts containing 150 µg of proteins were directly loaded onto an SDS gel; proteins were detected by ECL reagents (Bio-Rad) after Western blotting using antibodies as indicated in the figure legends.

Transient Transfection and Luciferase Assay-- H1299 cells (60% confluence in a 12-well plate) were transfected with a pCMV--galactoside reporter plasmid (0.2 ug) and a luciferase reporter plasmid (0.1 ug) driven by two copies of the p53RE motif derived from the mdm2 promoter (37), together with a combination of different plasmids (total plasmid DNA, 1 µg/well) as indicated in Fig. 5, using LipofectAMINE (Promega, WI). 48 h post-transfection, cells were harvested for luciferase assays as described previously (38). Luciferase activity was normalized by a factor of -galactosidase activity tested in the same assay.

Immunoprecipitation-Western Blot (IP-WB) Analysis-- Transfected H1299, 293, or MDM2 expression 293 cells were harvested for preparation of nuclear extracts. Nuclear extracts containing 250 µg of proteins were used for IP, followed by WB as previously described (37).

Chromatin Immunoprecipitation (ChIP)-PCR-- H1299 cells were transfected with pcDNA3-p53 or pCMV-MDM2 vector, alone or together. ChIP analysis was performed as described (42, 43) with minor modifications. Briefly, cells were cross-linked with a 1% formaldehyde solution in phosphate-buffered saline 36 h after transfection. The cross-linking was stopped by incubating the cells on 0.125 M glycine for 5 min. The cells were then harvested in 1 ml of lysis buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), 5 mM EDTA) containing the protease inhibitors pepstatin A (10 µg/ml), leupeptin (10 µg/ml), dithiothreitol (1 mM), phenylmethylsulfonyl fluoride (10 µg/ml). Cell lysates were sonicated 4 times for 15 s each at maximal setting to yield chromatin fragments of ~600 bp as assessed by agarose gel electrophoresis, followed by centrifugation for 10 min to remove the cell debris. Cell lysates were precleared with 50 µl of protein A-Sepharose/2 µg of sheared salmon sperm DNA slurry for 30 min at 4 °C. A total of 2 µg of anti-Myc or anti-FLAG antibodies was incubated with the precleared extracts overnight at 4 °C followed by incubation with protein A/G agarose for 2 h at 4 °C. The immunocomplexes were washed twice with lysis buffer, 4 times with IP wash buffer (100 mM Tris (pH 8.5), 50 mM LiCl, 1% Nonidet P-40, 1% deoxycholic acid), and twice more with lysis buffer. The precipitates were then extracted twice, each with 150 µl of IP elution buffer (50 mM NaHCO₃, 1% SDS). The eluates were pooled, mixed with 2 µl of 5 mg/ml RNase A and 12 µl of 5 M NaCl (to 0.2 M), and incubated at 65 °C for at least 6 h to reverse the formaldehyde cross-linking. DNA fragments were purified by phenol/chloroform extraction and ethanol precipitation and dissolved in 100 µl of sterile H₂O.

DNA samples were then analyzed with 25 or 28 cycles of PCR to amplify mdm2 and p21^waf1 promoter sequences containing the p53RE sequence. Each cycle consisted of denaturation at 94 °C for 30 s and annealing at 60 °C (mdm2 promoter) or 65 °C (p21^waf1 promoter) for 30 s, followed by extension at 72 °C for 2 min. A total of 0.5 µCi of [³²P]dCTP was added in each 50 µl of PCR mixture. The primers for amplifying the mdm2 promoter sequence (33) are 5'-GGTTGACTCAGCTTTTCCTCTTG-3' and 5'-GGAAAATGCATGGTTT-AAATAGCC-3' (inverse); the primers for amplifying the p21 promoter sequence (44) are 5'-GTGGCTCTGATTGGCTTTCTG-3' and 5'-CTGAAAACAGGCAGCCCAAGG-3' (inverse); the primers for amplifying the sequence located 2.5 kb upstream from the p53RE site of the mdm2 promoter (33) are 5'-TGAATCTACTCTTGGTGGTCC-3' and 5'-AAGGAAATTTGGGCTTTCGAC-3' (inverse). PCR products were resolved onto 6% polyacrylamide gel, dried, and exposed on film.

GST Fusion Protein Association Assay-- The fusion proteins were expressed in Escherichia coli and purified on a glutathione-Sepharose 12B column. Protein-protein association assays were conducted as reported (37) using fusion protein-containing beads. Approximately 250 ng of FLAG-PCAF or in vitro translated and ³⁵S-labeled PCAF (4 µl), PCAF/1-529 (4 µl), or PCAF/66-466 (8 µl) proteins were incubated with the GSH-Sepharose 4B beads (50% slurry) containing ~100 ng of GST-MDM2, GST-MDM2/1-150, GST-MDM2/295-491, GST-MDM2/384-491, GST-MDM2/425-491, or GST, respectively. One hour after incubation at room temperature, the mixtures were washed once in BC100 containing 0.1% Nonidet P-40, twice in SNNTE, and once in RIPA. Bound proteins were analyzed on a 10% SDS gel and detected by WB using the anti-FLAG or anti-PCAF monoclonal antibody to detect PCAF-GST-MDM2 interactions.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

MDM2 Inhibits PCAF-mediated p53 Acetylation in Vitro-- It has been shown that MDM2 inhibits p300/CBP-mediated p53 acetylation (14, 16). PCAF-mediated p53 acetylation can also be inhibited by the adenovirus-encoding E1B 55-kDa oncoprotein (26), which like MDM2 represses p53 activity by binding to its N terminus (45) and leads to p53 degradation (46). To determine whether MDM2 is also able to affect PCAF-mediated p53 acetylation, we performed an in vitro acetylation assay using purified proteins. As shown in Fig. 1A, as in the case of p300 (lane 3) (16), MDM2 also repressed PCAF-catalyzed p53 acetylation in a dose-dependent fashion in vitro (lanes 5 and 6). With 2-fold more MDM2 than PCAF in molar ratio, less than 10% of p53 molecules were acetylated based upon densitometry (lane 6). This result was reproducible. By contrast, the p53-binding defective mutant MDM2 in the same molar ratio was unable to inhibit p53 acetylation by PCAF (Fig. 1B). PCAF did not appear to acetylate MDM2 in vitro (Fig. 1C). Therefore, these results suggest that MDM2 can also inhibit p53 acetylation by PCAF, which specifically targets lysine 320 (12, 13). This inhibition requires the interaction between p53 and MDM2.

View larger version (35K): [in this window] [in a new window]   Fig. 1.   MDM2, but not N-MDM2, inhibits p53 acetylation by PCAF in vitro. A, the in vitro p53 acetylation assay was carried out as described under "Experimental Procedures." 75 ng of p53, 200 ng of p300, 250 ng of PCAF, and 500 nM of acetyl-CoA were used as indicated at the top. 200 ng (1×) and 400 ng (2×) of MDM2 were used. These proteins and acetylated p53 were detected with antibodies against MDM2, p53, and acetylated lysine. B, the same p53 acetylation assay as above was conducted except 200 (1×) and 400 (2×) ng of N-MDM2 mutant were used. C, PCAF did not acetylate MDM2 in vitro. The same acetylation assay was conducted as described above except 200 ng of GST-MDM2 (G-MDM2) and [1-14C]acetyl-CoA were also used here as substrates. The acetylated proteins were detected by autoradiography.

MDM2 Inhibits PCAF-mediated p53 Acetylation in Cells-- To further determine whether MDM2 inhibits PCAF-mediated p53 acetylation in cells, human p53-deficient small cell carcinoma H1299 cells were transfected with plasmids encoding p53 and/or FLAG-PCAF alone or together. Cells were harvested to assess the levels of these proteins and the acetylation status of p53 lysine 320 using antibodies specifically against acetylated lysine 320. As expected (12, 13), FLAG-PCAF, when overexpressed, acetylated p53 at lysine 320 without significantly affecting the level of p53 (Fig. 2A, compare lanes 2 and 4). The same transfection was carried out in the presence or absence of the MDM2-encoding plasmid. In this experiment, the proteasome inhibitor, MG132, was added to medium 12 h prior to harvesting cells to prevent p53 degradation mediated by MDM2. As shown in Fig. 2B, PCAF again acetylated the lysine 320 of p53 (lanes 3 and 4). However, overexpression of MDM2 significantly reduced the level of this acetylation (lane 5 with lane 6). This reduction was not due to the low level of p53, because the level of p53 did not change in the presence or absence of MDM2. Furthermore, this inhibition was not due to the nonspecific effect of the plasmid, because it was not observed when the MDM2 deletion lacking the amino acid 130-250 region was used (Fig. 2C). This deletion mutant was unable to affect PCAF-mediated p53 acetylation largely because it lacks the nuclear localization sequence and is excluded from the nucleus (data not shown) (47). These results thus indicate that MDM2 inhibits PCAF-mediated p53 acetylation in cells.

View larger version (34K): [in this window] [in a new window]   Fig. 2.   MDM2 inhibits p53 acetylation by PCAF in cells. A, H1299 cells (105 cells/60-mm dish) were transfected with plasmids encoding p53 (300 ng) and/or FLAG-PCAF (500 ng, 1× and 1 µg, 2×) as indicated at the top and harvested 36 h post-transfection. 100 µg of cell lysates were directly loaded onto a 10% SDS gel. Proteins and acetylated p53 were detected by WB using antibodies against FLAG (top), p53 (middle), and acetylated lysine 320 (bottom). Asterisks denote nonspecific signals. B, the same transfection-WB assay as described in panel A was carried out except that plasmids encoding MDM2 (1 µg, 1× and 2 µg, 2×) were also used as indicated at the top. C, the same transfection followed by WB analysis as that in panel B was conducted except that the plasmid encoding the MDM2 deletion lacking the amino acid 130-250 region was included (lanes 6 and 7).

MDM2 Directly Binds to PCAF in Vitro-- The finding that MDM2 inhibits PCAF-mediated p53 acetylation suggests a possible interaction between MDM2 and PCAF. To test this and also to define their potential binding domains, we performed a series of in vitro GST fusion protein-protein association assays. In the first experiment, purified FLAG-PCAF proteins were incubated with GST-MDM2 or GST-MDM2 deletion mutants as described under "Experimental Procedures." After rigorous washing, bound proteins were analyzed by SDS electrophoresis and Western blot, using anti-FLAG antibodies. As shown in Fig. 3A, PCAF bound to the full-length as well as the N-terminal region from amino acid 1 to 295. These bindings appeared to be specific because PCAF rarely bound to GST alone or GST fusion proteins containing the C terminus (amino acids 384-491) of MDM2. Because PCAF also interacted with the N terminus-deleted MDM2 (data not shown), which lacks amino acids 1-50, these results suggest that PCAF can bind to the amino acid 50-384 region of MDM2.

View larger version (47K): [in this window] [in a new window]   Fig. 3.   MDM2 binds to PCAF in vitro. A, the GST-MDM2 protein association assay was conducted as described under "Experimental Procedures" using purified proteins. FLAG-PCAF was detected by WB using antibodies against FLAG. B, the same GST-MDM2 protein association assay was performed as described in panel A. PCAF and its deletion mutants were in vitro translated and labeled with [35S]methionine. 80% of the inputs for wild type and deletion mutants of PCAF were directly loaded onto the SDS gel.

To map the MDM2-binding domain of PCAF, we carried out a similar GST-MDM2 pull-down experiment using in vitro translated and ³⁵S-labeled PCAF and deletion mutants. As shown in Fig. 3B, PCAF as well as the N terminus (amino acids 1-529), but not the N terminus-deleted, fragment of PCAF bound to the GST-MDM2 protein (compare lanes 1 and 2 with lane 3). This binding was specific because none of these PCAF proteins interacted with the GST-MDM2 C-terminal domain (lanes 4-6). Taken together, these results demonstrate that MDM2 directly interacts with the N terminus of PCAF in vitro, whereas PCAF appears to bind to the same region of MDM2 to which p300/CBP binds (48).

MDM2 Associates with PCAF in Cells-- To determine the interaction between MDM2 and PCAF in cells, human embryonic kidney 293 cells, which contain endogenous MDM2, were transfected with pCX-FLAG-PCAF or pCX alone. Cell lysates were prepared 48 h after transfection for immunoprecipitation using antibodies against FLAG, MDM2, and Jnk1, followed by Western blot with antibodies against MDM2 and FLAG. As shown in Fig. 4A, endogenous MDM2 proteins were co-immunoprecipitated with FLAG-PCAF by the anti-FLAG antibody in FLAG-PCAF expression cells but not in mock-transfected cells (lanes 1 and 2). Consistently, FLAG-PCAF was also co-immunoprecipitated with the endogenous MDM2 by the monoclonal MDM2 antibody in the FLAG-PCAF expression cells but not in mock-transfected cells (lanes 3 and 4). These results indicate that exogenous FLAG-PCAF associates with MDM2 in cells. This association was specific because none of these proteins was pulled down by the antibody against Jnk1 (lanes 5 and 6).

View larger version (36K): [in this window] [in a new window]   Fig. 4.   MDM2 binds to PCAF in cells. A, exogenous PCAF binds to endogenous MDM2. Human 293 cells (60% confluence per 6-cm dish) were transfected with 3 µg of plasmids encoding pCX-FLAG vector or pCX-FLAG-PCAF and harvested 40 h after transfection. 250 µg of cell lysates were used for IP with monoclonal antibodies against FLAG (FLAG), MDM2 (2A10), and Jnk1 (Jnk1), followed by WB with antibodies against MDM2 and FLAG. B, endogenous PCAF binds to endogenous MDM2. 250 µg of cell lysates prepared from human 293 cells (293) or stable HA-MDM2-expressing 293 cells (293(MDM2)) were used for IP with the antibodies anti-PCAF and -Jnk1, followed by WB with antibodies against PCAF and MDM2. H and L chains of IgG are indicated on right.

To make sure that endogenous PCAF interacts with MDM2, we conducted an additional immunoprecipitation-Western blot experiment using 293 cells and an MDM2-expressing 293 stable cell line. The MDM2 cell line was used because the level of endogenous MDM2 in 293 cells is low (Fig. 4A). As shown in Fig. 4B, both endogenous (lane 2) and exogenous (lane 1) MDM2 proteins were co-immunoprecipitated by the anti-PCAF antibody but not by the anti-Jnk1 antibody (lanes 3 and 4). Thus, this result confirms that MDM2 and PCAF interact with each other in cells.

MDM2 Inhibits PCAF-activated p53 Transcriptional Activity in Cells-- To determine the functional consequence of the inhibition of PCAF-mediated p53 acetylation by MDM2, we carried out transient transfection/luciferase assays. As shown in Fig. 5A, expression of the exogenous PCAF enhanced p53-dependent transcription as measured by the luciferase activity that was driven by the p21^waf1/cip1 promoter containing the p53RE motif. However, further expression of the exogenous MDM2 reversed the p53 activation by PCAF and brought p53-dependent luciferase activity down almost to the basal level. This decrease was not due to the loss of p53 proteins, because the level of p53 did not change dramatically in the presence of the proteasome inhibitor, MG132. This result, which was reproducible, demonstrates that MDM2 can also inhibit PCAF-enhanced p53 transcriptional activity without apparently affecting its level. Together with our previous report (16), this suggests that MDM2 negatively regulates p53 activity at least in part by inhibiting its acetylation, which is catalyzed by p300/CBP and by PCAF.

View larger version (30K): [in this window] [in a new window]   Fig. 5.   MDM2 reverses the activation of p53 activity by PCAF. A, MDM2 inhibits PCAF-activated p53 transcriptional activity. H1299 cells were used for a transfection/luciferase assay as described under "Experimental Procedures." Plasmids encoding p53 (50 ng), PCAF (100 ng), and/or MDM2 (200 ng, 1× and 400 ng, 2×) were used. The levels of PCAF, MDM2, and p53 were detected by WB using antibodies against these proteins as shown in the bottom panel. Luciferase activity is presented in arbitrary units. Asterisks denote nonspecific signals. B and C, MDM2 co-resides with p53 at the p53-responsive mdm2 and p21 promoters. CHiP was conducted as described under "Experimental Procedures." The top panel shows the PCR products from the immunoprecipitates using antibodies against p53 and HA-MDM2. C, protein levels of these proteins and the endogenous p21. 150 µg of total proteins were loaded onto an SDS gel. D, a model of p53 inactivation by MDM2. Arrows denote stimulation, and bars indicate inhibition.

MDM2 Co-resides with p53 at the Endogenous p53RE Motifs of the mdm2 and p21 Promoters-- Because MDM2 can interact with p53RE-bound p53 in vitro (49), it is possible that MDM2 may repress p53 activity by directly associating with the promoter-bound p53 in cells. To test this idea, we performed a set of chromatin-immunoprecipitation assays, following transient transfection. As described under "Experimental Procedures," H1299 cells were transfected with plasmids encoding p53 or MDM2 alone or together. Immunoprecipitations were conducted with polyclonal anti-p53 and monoclonal anti-MDM2 antibodies. PCR reactions were carried out using primers that encompass the p53RE-containing sequence of either the mdm2 or the p21^waf1/cip1 promoter. The results are shown in Fig. 5B. As expected, p53 resided at both the mdm2 and p21 promoters. Interestingly, MDM2 also localized at these promoters. This must be due to the association of MDM2 with p53, because MDM2 does not bind to DNA. In fact, without p53, overexpression of MDM2 (Fig. 5C) alone did not display detectable PCR products from the promoters (Fig. 5B, lane 5). Furthermore, when nonspecific primers upstream from the mdm2 promoter were used, no PCR product was detected from the immunoprecipitates with either anti-p53 or anti-HA-MDM2 antibodies. Consistently, MDM2 significantly repressed p53-mediated expression of the endogenous p21^waf1/cip1 (Fig. 5C). Hence, these results demonstrate that MDM2 indeed associates with the promoter-bound p53, and this association might also play a role in negatively modulating p53 transcriptional activity.

We previously showed (16) that MDM2 inhibited p300-catalyzed p53 acetylation by directly associating with these two proteins. Here, we have extended this work by demonstrating that MDM2 is also able to negate PCAF-mediated p53 acetylation at lysine 320. MDM2 inhibited PCAF-mediated p53 acetylation both in vitro and in cells (Figs. 1 and 2). As in the case of p300 (16), the N-terminal domain of MDM2 is required for this inhibition, suggesting that interaction with p53 is essential for the inhibitory effect of MDM2 on p53 acetylation by the acetylases that have been tested. Interestingly, MDM2 also directly interacted with PCAF in vitro and in cells (Figs. 3 and 4). Similar to p300 (14, 48), PCAF bound to the MDM2 region from amino acids 50 to 350 (Fig. 3A and data not shown). Functionally, MDM2 also repressed PCAF-enhanced p53 transcriptional activity. Because MDM2 co-resided with p53 on the endogenous p53-responsive promoters and repressed p53-dependent expression of the endogenous p21^waf1/cip1 (Fig. 5, B and C), MDM2 might block p53 function by interfering with the communication between p53 and the transcriptional machinery (50, 51). Yet it needs to be tested whether MDM2 inhibits p53 acetylation while it sits with p53 on the promoters.

This study consistent with previous reports (14, 16) suggests a general model for MDM2 repression of p53 function after DNA damage (Fig. 5D). In response to DNA damage, p53 is activated to induce expression of its target genes, including mdm2. Overexpression of MDM2, on the one hand, binds to p53 and its acetylases, such as p300/CBP or PCAF, to prevent p53 modifications by these proteins. In addition, deacetylases, such as HDCA1 and Sir2, are activated by unknown mechanisms to deacetylate p53 (21-24). Whether MDM2 promotes this deacetylation is not yet clear. Inhibition of p53 acetylation or deacetylation at the C-terminal lysines residues would allow MDM2 to efficiently ubiquitinate the same lysine residues of p53 (52), thus leading to p53 degradation through the ubiquitin-mediated proteasome machinery (27, 30, 31), although evidence linking p53 ubiquitination to its degradation has not yet been obtained. One study (53) suggests that MDM2 might target multiple C-terminal lysines for mono-ubiquitination. If this is true, it is likely that MDM2 might target lysine 320 for ubiquitination as well. On the other hand, MDM2 also blocks p53 transcriptional activity by directly associating with this activator on the promoters and by inhibiting its acetylation at the C-terminal lysines. Through these multiple mechanisms, MDM2, as a feedback regulator (33), effectively controls or balances p53 activity after DNA damage.

	ACKNOWLEDGEMENTS

We thank Hunjoo Lee for preparing some reagents for this study, Jiandong Chen for the MDM2 mutant plasmids, David M. Keller for critically reading this manuscript, and other members of the lab for active discussions.

	FOOTNOTES

^* This work was supported by grants (to H. L.) from the National Institutes of Health and the American Cancer Society.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97201. Tel.: 503-494-7414; Fax: 503-494-8393; E-mail: luh@ohsu.edu.

Published, JBC Papers in Press, June 14, 2002, DOI 10.1074/jbc.M204078200

	ABBREVIATIONS

The abbreviations used are: CBP, CREB-binding protein; CREB, cAMP-response element-binding protein; HA, hemagglutinin; PCAF, p300/CBP-associated factor; IP, immunoprecipitation; ChIP, chromatin IP; GST, glutathione S-transferase; WB, Western blot.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				Y. Jin, S. X. Zeng, X.-X. Sun, H. Lee, C. Blattner, Z. Xiao, and H. Lu MDMX Promotes Proteasomal Turnover of p21 at G1 and Early S Phases Independently of, but in Cooperation with, MDM2 Mol. Cell. Biol., February 15, 2008; 28(4): 1218 - 1229. [Abstract] [Full Text] [PDF]

				S. Ohkubo, T. Tanaka, Y. Taya, K. Kitazato, and C. Prives Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription J. Biol. Chem., June 23, 2006; 281(25): 16943 - 16950. [Abstract] [Full Text] [PDF]

				M.-S. Dai and H. Lu Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5 J. Biol. Chem., October 22, 2004; 279(43): 44475 - 44482. [Abstract] [Full Text] [PDF]

				G. Legube, L. K. Linares, S. Tyteca, C. Caron, M. Scheffner, M. Chevillard-Briet, and D. Trouche Role of the Histone Acetyl Transferase Tip60 in the p53 Pathway J. Biol. Chem., October 22, 2004; 279(43): 44825 - 44833. [Abstract] [Full Text] [PDF]

				M.-S. Dai, S. X. Zeng, Y. Jin, X.-X. Sun, L. David, and H. Lu Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition Mol. Cell. Biol., September 1, 2004; 24(17): 7654 - 7668. [Abstract] [Full Text] [PDF]

				Y. Jin, S. X. Zeng, H. Lee, and H. Lu MDM2 Mediates p300/CREB-binding Protein-associated Factor Ubiquitination and Degradation J. Biol. Chem., May 7, 2004; 279(19): 20035 - 20043. [Abstract] [Full Text] [PDF]

				S. M. Frisch E1A as a Tumor Suppressor Gene: Commentary re S. Madhusudan et al. A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clin Cancer Res 2004;10:2905-2907. Clin. Cancer Res., May 1, 2004; 10(9): 2905 - 2907. [Full Text] [PDF]

				C. D. Knights, Y. Liu, E. Appella, and M. Kulesz-Martin Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification J. Biol. Chem., December 26, 2003; 278(52): 52890 - 52900. [Abstract] [Full Text] [PDF]

				T. Iwakuma and G. Lozano MDM2, An Introduction Mol. Cancer Res., December 1, 2003; 1(14): 993 - 1000. [Abstract] [Full Text] [PDF]

				R. Harrod, J. Nacsa, C. Van Lint, J. Hansen, T. Karpova, J. McNally, and G. Franchini Human Immunodeficiency Virus Type-1 Tat/Co-activator Acetyltransferase Interactions Inhibit p53Lys-320 Acetylation and p53-responsive Transcription J. Biol. Chem., March 28, 2003; 278(14): 12310 - 12318. [Abstract] [Full Text] [PDF]

				S. X. Zeng, Y. Jin, D. T. Kuninger, P. Rotwein, and H. Lu The Acetylase Activity of p300 Is Dispensable for MDM2 Stabilization J. Biol. Chem., February 21, 2003; 278(9): 7453 - 7458. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 277/34/30838    most recent M204078200v1 Alert me when this article is cited Alert me if a correction is posted